Floatz logo

Tisagenlecleucel

B-cell Acute Lymphoblastic Leukemia

Assistance Publique - Hôpitaux de ParisCell therapyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
73/ 100

Competitive context

48 Active assets in the B-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Blinatumomab
SWOG Cancer Research Network
Phase 4BB
Chimeric Antigen Receptor Modified T Cells Infusion
Shenzhen Geno-Immune Medical Institute
Phase 2BB
cd19-ucart
Beijing GoBroad Hospital
Phase 2BB
Fludarabine
National Cancer Institute (NCI)
Phase 3B
cd22 car-transduced t cells
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
Primary Mediastinal Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →